Sam Chun Dang Pharm Signs Exclusive Japan Sales and Supply Deal With Daiichi Sankyo Espha for SCD411
Bitget2026/11/02 07:39- Sam Chun Dang Pharm entered an exclusive Japanese sales and supply agreement with Daiichi Sankyo Espha for SCD411 on November 2, 2026.
- The aflibercept biosimilar's Japanese commercialization will proceed on schedule under the existing marketing authorization held by Sam Chun Dang.
- The new partnership replaces an agreement with Senju Pharmaceutical, terminated by mutual consent the same day.
- Senju will receive USD 4 million for returning exclusive sales rights; the termination carries no penalties or damages.
- Previously received upfront and milestone payments totaling USD 17.2 million remain nonrefundable; outstanding milestones will not be received.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
